Relationship between chronotropic incompetence and β-blockers based on changes in chronotropic response during

Nami Takano1, Haruhito Takano2, Taira Fukuda3

  • 1Department of Cardiovascular Medicine, The University of Tokyo Hospital, 7-3-1Hongo, Bunkyo-Ku, Tokyo 113-8655, Japan.

Insights

Chronotropic incompetence, an impaired heart rate response to exercise, can improve with cardiac rehabilitation. Beta-blockers significantly influence the metabolic chronotropic relationship during exercise testing.

Area of Science:

  • Cardiology
  • Exercise Physiology

Background:

  • Chronotropic incompetence (CI) is a common condition in cardiovascular disease patients, characterized by an inadequate heart rate (HR) increase during physical activity.
  • Assessing CI is crucial for optimizing exercise capacity and rehabilitation outcomes in these individuals.

Purpose of the Study:

  • To evaluate changes in chronotropic response (CR) during cardiopulmonary exercise testing (CPET) in patients undergoing cardiac rehabilitation.
  • To investigate the impact of beta-blocker medication on CR and the metabolic chronotropic relationship (MCR).

Main Methods:

  • Patients with CI undergoing cardiac rehabilitation performed CPET.
  • The metabolic chronotropic relationship (MCR) was calculated at four exercise stages using the Wilkoff model.
  • Improvement in CR was defined as an increase in MCR at three or more stages.

Main Results:

  • Patients with elevated BNP levels exhibited lower MCR values across all exercise stages.
  • Beta-blocker use was prevalent in patients showing improved peak VO2 and anaerobic threshold (AT), and in those with improved CR.
  • The MCR pattern differed based on beta-blocker use: MCR-AT was lower than MCR-Rc in non-users, and higher in users.

Conclusions:

  • An attenuated HR response during exercise may be more pronounced in the initial stages.
  • Comparing MCR-AT and MCR-Rc effectively identifies the influence of beta-blockers on HR response during CPET.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.8K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.7K